CG Oncology (CGON) Non-Current Assets (2023 - 2026)

CG Oncology has reported Non-Current Assets for 4 years, with the latest figure at $33.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 22.71% year-over-year to $33.1 million; the trailing twelve-month figure through Mar 2026 stood at $127.8 million (up 349.39% YoY), and the FY2025 full-year result was $32.1 million, up 5371.38% from the prior year.
• Non-Current Assets for Q1 2026 stood at $33.1 million, up from $32.1 million in the prior quarter.
• The five-year high for Non-Current Assets was $34.1 million in Q3 2025, with the low at $391000.0 in Q3 2024.
• Historically, Non-Current Assets has averaged $16.2 million across 4 years, with a median of $16.1 million in 2023.
• Annual changes were most pronounced in 2024 — Non-Current Assets plunged 88.66% — and 2025, when it jumped 8627.11%.
• CG Oncology's Non-Current Assets stood at $5.2 million in 2023, then sank by 88.66% to $587000.0 in 2024, then soared by 5371.38% to $32.1 million in 2025, then climbed by 3.12% to $33.1 million in 2026.
• The last three Non-Current Assets figures came in at $33.1 million (Q1 2026), $32.1 million (Q4 2025), and $34.1 million (Q3 2025), per Business Quant data.